1、Table 1:Sales by Segment 1Table 2:Sales by Geographic Area2Table 3:Sales of Key Products/Franchises3-7Table 4:Condensed Consolidated Statement of Earnings-QTD8Table 5:Condensed Consolidated Statement of Earnings-YTD9Table 6:Non-GAAP Adjusted Operational Sales Growth-QTD10Table 7:Non-GAAP Adjusted Op

2、erational Sales Growth-YTD11Table 8:Non-GAAP Adjusted Net Earnings12Table 9:Non-GAAP P&L by Segment Reconciliation 2025-QTD13Table 10:Non-GAAP P&L by Segment Reconciliation 2024-QTD14Table 11:Non-GAAP P&L by Segment Reconciliation 2025-YTD15Table 12:Non-GAAP P&L by Segment Reconciliation 2024-YTD16T

3、hird Quarter 2025Other Financial DisclosuresTable of ContentsJohnson&Johnson and SubsidiariesSupplementary Sales Data(Unaudited;Dollars in Millions)Percent Change20252024TotalOperationsCurrency20252024TotalOperationsCurrencySales to customers bysegment of businessInnovative Medicine U.S.9,402$8,871

4、6.0%6.0 -26,655$24,993 6.7%6.7 -International6,161 5,709 7.9 4.3 3.6 17,983 17,639 1.9 1.3 0.6 15,563 14,580 6.8 5.3 1.5 44,638 42,632 4.7 4.5 0.2 MedTech U.S.4,306 4,038 6.6 6.6 -12,902 12,105 6.6 6.6 -International4,124 3,853 7.0 4.5 2.5 12,089 11,564 4.5 3.9 0.6 8,430 7,891 6.8 5.6 1.2 24,991 23,

5、669 5.6 5.3 0.3 U.S.13,708 12,909 6.2 6.2 -39,557 37,098 6.6 6.6 -International10,285 9,562 7.6 4.4 3.2 30,072 29,203 3.0 2.3 0.7 Worldwide23,993$22,471 6.8%5.4 1.4 69,629$66,301 5.0%4.7 0.3 Note:Percentages have been calculated using actual,non-rounded figures and,therefore,may not recalculate prec

6、isely.THIRD QUARTERNINE MONTHS Percent ChangeJohnson&Johnson and SubsidiariesSupplementary Sales Data(Unaudited;Dollars in Millions)Percent Change20252024TotalOperationsCurrency20252024TotalOperationsCurrencySales to customers bygeographic areaU.S.13,708$12,909 6.2%6.2 -39,557$37,098 6.6%6.6 -Europe